Between Pfizer e Biontech on the one hand and Modern on the other it is now war open on patents anti-Covid and, consequently, on the very rich royalties. The pandemic slows down, Big Pharma's profits and stock prices plummet but the legal battles multiply. That of Moderna against Pfizer and Biontech is emblematic. The legal challenge was opened by Moderna which since last August has accused the two major rival houses of violating some patents relating to the technology of theRNA, messenger on which the Spikevax vaccine is based. But now the American pharma giant and its German partner Biontech have gone on the counterattack, clearly rejecting Moderna's accusations on which they have turned their criticisms. Pfizer and Biontech say their vaccine "is undeniably different" from Moderna's.
PATENT WAR: THE REAL REASONS FOR THE LEGAL BATTLE
But what's really behind the war between the Big's pharma? Many things. Firstly, the fight for the technological leadership of vaccines well beyond the anti-Covid horizon and with an eye to future pharmacological and commercial scenarios and the conquest of royalties. Secondly, the decline of the pandemic has led to a clear reduction in profits of the pharmaceutical companies that have most committed themselves and invested in anti-Covid research. And with the virus and profits down, the quotes of MY BAG they have plummeted. In recent days, the MF newspaper has published a merciless table on the collapse of Big Pharma's stock market performance. The maths are quickly made and are more eloquent than ever.
MODERNA, BIONTECH, PFIZER: ALL THE LOSSES AFTER THE INITIAL TRIUMPHS
Since the beginning of the pandemic, the one who has lost the most, after the initial triumphs, has been Moderna, with a catastrophic collapse of 746,1%, followed by that of Biontech (-453,3%) while Pfizer has been able to contain the stock market losses which stopped at -40,8%. And how is this year going? In 2022, the loser is Curevac (-78,2%) but also Biontech (-36,5%) and Moderna (-31,7%) are not doing well. Again this year, Pfizer is the one who defends itself best, limiting losses to 15,8%. And if you count and the stock market cry, i tribunal take the place of markets.
